(benzo[b]thiophene-2-carbonyl)-l-leucine | 215941-14-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (benzo[b]thiophene-2-carbonyl)-l-leucine
• 英文别名: N-benzo[b]thiophene-2-ylcarbonyl-L-leucine；N-(benzothiophene-2-carbonyl)amino-leucine；N-(1-benzothien-2-ylcarbonyl)-L-leucine；(S)-2-[(1-benzo[b]thiophen-2-yl-methanoyl)-amino]-4-methyl-pentanoic acid；(2S)-2-(1-benzothiophene-2-carbonylamino)-4-methylpentanoic acid
• CAS: 215941-14-3
• 化学式: C₁₅H₁₇NO₃S
• mdl: MFCD09802219
• 分子量: 291.371
• InChiKey: PLZMSWMCRNQSIV-NSHDSACASA-N

物化性质

• 沸点：
  550.2±30.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (benzo[b]thiophene-2-carbonyl)-l-leucine 在 乙酰氧肟酸 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 11.0h， 生成 N-((S)-1-(4-(((2-chloro-4-methoxyphenyl)sulfonyl)-l-seryl)piperazin-1-yl)-4-methyl-1-oxopentan-2-yl)benzo[b]thiophene-2-carboxamide
  参考文献：
  名称：

  Synthesis and in vitro evaluation of new TRPV4 ligands and biodistribution study of an 11C-labeled radiotracer in rodents

  摘要：

  Nine new compounds targeting the transient receptor potential vanilloid-4 (TRPV4) were synthesized and their biological activities toward TRPV4 were determined using freshly isolated mouse skin macrophages through live cell Ca2+ imaging assay. Three compounds 4b, 4c, and 4i exhibited higher percentages of in vitro activation of TRPV4 as 48.1%, 59.3% and 33.5%, which are comparable to 56.4% activation response of the reported TRPV4 agonist GSK1016790A (3). The compound 4i was chosen for 11C-radiosynthesis using its phenol precursor 4g to reacted with [11C]methyl iodide. The radiosynthesis was achieved with good radiochemical yield (16 ± 5%), high chemical and radiochemical purity (>95%), and high molar activity (16-21 GBq/μmol, decay corrected to the end of bombardment, EOB n ≥ 4). Furthermore, the initial ex vivo biodistribution study in rats showed that [11C]4i had higher uptake in kidney, liver and small intestine compared to other tissues with rapid washout.

  DOI：

  10.1016/j.bmcl.2020.127573
• 作为产物：
  描述：

  苯并噻吩-2-羧酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 生成 (benzo[b]thiophene-2-carbonyl)-l-leucine
  参考文献：
  名称：

  [EN] TRPV4 ANTAGONISTS
  [FR] ANTAGONISTES DE TRPV4

  摘要：

  这项发明涉及二氮杂双环[2.2.1]庚-2-基类似物，含有它们的药物组合物以及它们作为TRPV4拮抗剂的用途。

  公开号：

  WO2009111680A1

文献信息

• Cysteine protease inhibitors
  申请人：Naeja Pharmaceutical Inc.

  公开号：US06635621B1

  公开（公告）日：2003-10-21

  This invention relates to derivatives of alpha-amino acid amides, to pharmaceutical compositions containing such compounds, and to their use in medicine as inhibitors of cysteine proteases, particularly the cathepsins. A compound of formula (I) is described or a pharmaceutically acceptable salt, hydrate or solvate thereof. Pharmaceutically acceptable salts of the compounds of this invention include the sodium, potassium, magnesium, calcium, hydrogen chloride, tartaric acid, succinic acid, fumaric acid and p-toluenesulfonic acid salts.

  本发明涉及α-氨基酸酰胺的衍生物，包含这类化合物的药物组合物，以及它们在医学上作为半胱氨酸蛋白酶抑制剂的用途，特别是对半胱氨酸蛋白酶的抑制作用。描述了式(I)的化合物或其药用可接受的盐、水合物或溶剂合物。本发明化合物的药用可接受的盐包括钠、钾、镁、钙、盐酸氢、酒石酸、琥珀酸、富马酸和对甲苯磺酸盐。
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20020013360A1

  公开（公告）日：2002-01-31

  The invention relates to 3-hydroxy-and 3-keto-cyclohetero-substituted leucine compounds that are inhibitors of cysteine proteases, particularly cathepsin K, and are useful in the treatment of diseases in which inhibition of bone loss is a factor. The 3-hydroxy-or 3-keto-moiety is bonded to a tetrahydrothiophene, tetrahydrothiopyran, tetrahydrofuran or tetrahydropyran ring.

  本发明涉及3-羟基和3-酮基环杂基取代的亮氨酸化合物，它们是半胱氨酸蛋白酶抑制剂，特别是卡他普星K的抑制剂，并且在治疗骨质流失是一个因素的疾病中有用。 3-羟基或3-酮基基团与四氢噻吩，四氢噻吩，四氢呋喃或四氢吡喃环结合。
• Novel Compounds
  申请人：Casillas Linda N.

  公开号：US20080318945A1

  公开（公告）日：2008-12-25

  This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted piperazines, according to Formula I A compound of formula I wherein Z is bond or NH; R 1 is aryl or optionally substituted heteroaryl; R 2 is H, optionally substituted C 1-6 alkyl, or optionally substituted C 2-6 alkenyl; R 3 and R 7 are independently H, optionally substituted C 1-6 alkyl, or aryl; R 4 is H or optionally substituted C 1-6 alkyl; R 5 is H or C 1-6 alkyl; R 6 is H or C 1-6 alkyl; and X and X′ are independently O or H 2 ; or wherein R 3 and R 4 together form a part of morpholinyl, piperadinyl, or aziridinyl ring; and pharmaceutically acceptable salts thereof.

  本发明涉及一种新型化合物，可用于治疗与TRPV4通道受体相关的疾病。更具体地说，本发明涉及某些取代哌嗪，其化学式为IA式的化合物，其中Z为键或NH；R1为芳基或可选取代的杂环芳基；R2为H、可选取代的C1-6烷基或可选取代的C2-6烯基；R3和R7独立地为H、可选取代的C1-6烷基或芳基；R4为H或可选取代的C1-6烷基；R5为H或C1-6烷基；R6为H或C1-6烷基；而X和X'独立地为O或H2；或其中R3和R4一起形成吗啉基、哌啶基或氮杂环环的一部分；以及其药学上可接受的盐。
• Method for Activating Trpv4 Channel Receptors by Agonists
  申请人：Kumar Sanjay

  公开号：US20070259856A1

  公开（公告）日：2007-11-08

  This invention relates to methods for activating a TRPV4 channel receptor, thereby reducing the production and/or release of matrix degrading enzymes by a cell expressing a TRPV4 channel receptor, thereby reducing the breakdown of an extra-cellular matrix. Also contemplated within the scope of the invention are methods of attenuating the inhibition of matrix production.

  本发明涉及激活TRPV4通道受体的方法，从而减少表达TRPV4通道受体的细胞产生和/或释放基质降解酶，从而减少细胞外基质的分解。本发明还考虑了减轻基质生产抑制的方法。
• Acyclic 1,3-Diamine And Uses Therefor
  申请人：Casillas N. Linda

  公开号：US20070259965A1

  公开（公告）日：2007-11-08

  This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino-azepines, according to Formula I or pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein: R 1 is aryl optionally substituted with CN, NO 2 , halogen or H; R 2 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 heterocycloalkyl; R 3 is H, OH, O—C 1 -C 6 alkyl, SH, S—C 1 -C 6 alkyl, or F; R 4 is H, C 1 -C 6 alkyl R 5 is iso-butyl, cyclohexylmethyl, or cyclopentylmethyl; and R 6 is aryl, heteroaryl.

  本发明涉及一种新型化合物，可用于治疗与TRPV4通道受体相关的疾病。更具体地说，本发明涉及按照公式I或其药学上可接受的盐、水合物或溶剂化物所替代的氨基-氮杂环化合物，其中：R1是芳基，可选用CN、NO2、卤素或H进行取代；R2是H、C1-C6烷基、C3-C7环烷基或C3-C7杂环烷基；R3是H、OH、O-C1-C6烷基、SH、S-C1-C6烷基或F；R4是H或C1-C6烷基；R5是异丁基、环己基甲基或环戊基甲基；R6是芳基或杂芳基。